Last year, Heron Therapeutics Inc generated 96.76M USD for its biggest-performing segment, CINVANTI. The United States made the largest contribution, accounting for 154.90M USD last year. For the latest quarter, Heron Therapeutics Inc reported the revenue of 21.79M USD for the period ending 2026-06-30, which came from the top-performing segment, CINVANTI. United States contributed the highest revenue, at 37.67M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

CINVANTI

SUSTOL

ZYNRELEF

APONVIE

FY2025

FY2024

FY2023

CINVANTI

96.76M(62.46%)

100.08M(69.36%)

94.87M(74.67%)

SUSTOL

38.07M(24.58%)

14.14M(9.80%)

13.06M(10.28%)

ZYNRELEF

11.57M(7.47%)

25.55M(17.71%)

17.73M(13.95%)

APONVIE

8.50M(5.49%)

4.52M(3.13%)

1.39M(1.09%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

FY2025

FY2024

FY2023

United States

154.90M(100.00%)

144.28M(100.00%)

127.04M(100.00%)